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Atomoxetine Treatment in Children and
Adolescents with Attention-Deficit 
Hyperactivity Disorder: What Are the Long-Term
Health-Related Quality-of-Life Outcomes?
Amy R. Perwien, Ph.D.,1 Christopher J. Kratochvil, M.D.,2 Douglas E. Faries, Ph.D.,1
Brigette S. Vaughan, B.S.N.,2 Thomas Spencer, M.D.,3 and Ronald T. Brown, Ph.D.4
ABSTRACT
Objective: Numerous investigations have examined the efficacy of pharmacological treat-
ment for attention-deficit/hyperactivity disorder (ADHD) in children. However, relatively
few studies have addressed the impact of treatment on long-term subjective, psychosocial
outcomes, such as health-related quality of life (HRQL). This study examines the long-term
effects of pharmacological treatment with atomoxetine on HRQL in children and adolescents
with ADHD.
Methods: Participants included 6- to 17-year-old children and adolescents (n = 912) with
ADHD enrolled in a 24-month, multicenter, open-label trial of atomoxetine. Outcomes in-
cluded clinician ratings of ADHD, parent ratings of ADHD, and a widely used measure of
HRQL (The Child Health Questionnaire (CHQ)). Treatment response rates were calculated
based on a CHQ improvement of at least 1 standard error of measurement.
Results: Significant improvements in HRQL were found following both acute and long-term
treatment for psychosocial but not physical health. Of participants who completed treatment (n
= 312 or 34.2% of those enrolled), 81% responded to acute treatment and 78% responded to long-
term treatment. Improvements noted after acute treatment were maintained during long-term
treatment with the majority of participants (86%) continuing to respond to treatment.
Conclusions: Atomoxetine is associated with improvements in HRQL, and the improve-
ments are generally stable over time.
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INTRODUCTION
ATTENTION-DEFICIT/HYPERACTIVITY DISORDER(ADHD) is a frequently occurring child-
hood mental health disorder that often results
in a number of functional impairments includ-
ing academic difficulties (Faraone et al. 2001;
Pastor and Reuben 2002), social skills deficits
(Bagwell et al. 2001; Greene et al. 2001;
Thurber et al. 2002), and strained family rela-
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tionships (Johnston and Mash 2001). In addi-
tion, longitudinal studies have indicated that
ADHD is associated with higher rates of sub-
stance use (Weiss et al. 1985; Biederman et al.
1998; Tapert et al. 2002) as well as lower aca-
demic and occupational attainment (Man-
nuzza et al. 1997; Hansen et al. 1999; Barkley et
al. 2002).
Given the impact of ADHD on multiple do-
mains of functioning and the chronic nature of
the disorder, ADHD recently has been viewed
as a disorder that can significantly impact
health-related quality of life (HRQL). HRQL is
distinct from both disorder symptoms and
objective functional outcomes in that it is
multidimensional and subjectively examines
physical, social, and psychological aspects of
health (Wallander et al. 2001). In children and
adolescents with ADHD, HRQL is related to
disease symptomatology, but provides infor-
mation beyond that obtained from traditional
symptom measures (Matza et al. 2004). When
comparing children with ADHD to normative
data, worse HRQL in psychosocial health has
been noted in children with ADHD (Landgraf
et al. 1996). Consistent findings were found in
a large-scale study of Australian children and
adolescents (n = 3597), even after controlling
for age, gender, family structure, and health
status (Sawyer et al. 2002). These studies of
HRQL in children with ADHD suggest that
this is an important outcome that is not fully
captured by traditional ADHD symptom mea-
sures. Not surprisingly, studies have consis-
tently indicated that the impact of ADHD on
HRQL seems to be specific to psychosocial
health as opposed to physical health (Landgraf
et al. 1996; Sawyer et al. 2002).
With regard to the management of ADHD
and its associated symptoms, pharmacotherapy
and behavior therapy are considered to be the
standard of care. In fact, a number of studies
have attested to the efficacy of these treatments
in the management of the disorder (for reviews,
see Pelham et al. 1998; Barkley 2002; Greenhill,
et al. 2002; Kratochvil et al., 2003). Although nu-
merous studies have addressed the effect of
treatment on core ADHD symptoms, HRQL has
not been addressed as frequently in well-con-
trolled trials of ADHD treatments. This is de-
spite the fact that the American Academy of
Pediatrics (AAP) has suggested that treatment
outcomes should include improved functional-
ity as well as decreased core symptomatology
(American Academy of Pediatrics 2001). Some
of the functional improvements areas high-
lighted by the AAP can be captured by psy-
chosocial aspects of HRQL measures as has
been done in double-blind, placebo-controlled
trials of atomoxetine. These trials have noted
that atomoxetine improved psychosocial
HRQL as well as core ADHD symptoms
(Michelson et al. 2001; Perwien et al. 2004).
Although well-designed long-term studies,
such as the landmark Multimodal Treatment
Study of Attention Deficit/Hyperactivity Dis-
order (MTA Cooperative Group, 1999), have
noted the effectiveness of medication treat-
ment for core ADHD symptomatology, HRQL
has only recently been examined. A 9-month
randomized, double-blind, placebo-controlled
study of atomoxetine treatment responders
found that medication was superior to placebo
in improving HRQL as well as in maintaining
core ADHD symptom response (Michelson et
al. 2004).
In summary, research has shown both short-
and long-term negative outcomes associated
with childhood ADHD. Although clinical tri-
als have consistently supported the efficacy of
pharmacotherapy, less data are available on
the long-term effects of these medications.
Even though the psychosocial aspects of
HRQL have been identified as an area of con-
cern for children with ADHD, few studies
have systematically examined the effect of
treatment on HRQL, let alone response to
long-term treatment. The present study builds
on earlier research that supported the positive
effect of acute treatment with atomoxetine on
HRQL. Although core symptom response to
atomoxetine was examined in this study, the
primary objective of this report is to investi-
gate the long-term outcome of atomoxetine
treatment on HRQL. It was hypothesized that
psychosocial HRQL would improve following
10-week acute treatment and would be main-
tained over a 24-month treatment phase.
Given that previous research indicates poor
HRQL in ADHD is specifically associated with
psychosocial health, no changes in physical
health following treatment were expected.
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METHODS
Participants
Children and adolescents diagnosed with
ADHD who ranged in age from 6 to 17 years
were enrolled in a multicenter (55 sites), open-
label trial of atomoxetine. Participants were re-
cruited through physician referrals and by
advertisement. To qualify for participation in
the study, participants had to meet diagnostic
and severity criteria for ADHD. Potential par-
ticipants were excluded if they had a history of
bipolar disorder or psychosis (including use of
antipsychotic medication within 8 weeks of
study enrollment), cognitive impairment (i.e.,
IQ <80), seizure disorder, and/or significant
medical condition(s). Children also were ex-
cluded if they had a history of alcohol or drug
abuse within the past 3 months. Although a
history of psychotropic medication use was
permitted, participants were required to be
free of any psychotropic medication, including
stimulant medications, and health food sup-
plements with purported central nervous sys-
tem activity for at least 5 half lives prior to
study enrollment. For example, children had
to be free of short-acting stimulants for at least
24 hours and long-acting stimulants for 1–2
days (Concerta® and Adderall XR® for at least
17.5 hours and 48 hours, respectively).
Measures
Trained mental health providers (e.g., psy-
chiatrists, psychologists) administered the
Schedule for Affective Disorders and Schizo-
phrenia for School-Age Children–Present/
Lifetime Version (K-SADS-PL; Ambrosini 2000)
to document the presence of ADHD and to de-
termine the subtype (combined, predominately
inattentive, predominately hyperactive/im-
pulsive). The K-SADS-PL is a semistructured
psychiatric interview that allows the inter-
viewer to incorporate data from multiple infor-
mants (i.e., parent and child) to determine
diagnoses. The behavioral (ADHD, opposi-
tional defiant disorder, conduct disorder), af-
fective, and anxiety disorder sections were
administered. The K-SADS has been found to
have adequate reliability and validity (Am-
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brosini 2000). To assess ADHD symptom sever-
ity, the clinician-rated version of the ADHD
Rating Scale (ADHD-RS; Faries et al. 2000) was
completed by trained mental health providers,
on the basis of an interview with the parent/
guardian, while the parents directly rated the
child’s behavior using the Conners’ Parent Rat-
ing Scale–Revised: Short-Form (CPRS-R:S; Con-
ners 1997). The ADHD-RS includes 18 items,
each of which corresponds to a specific ADHD
symptom. For entry into the study, children
were required to be at least one standard devia-
tion (SD) above the norm on the ADHD-RS for
their diagnostic subtype. The CPRS-R:S is a 27-
item rating scale that assesses behavioral prob-
lems related to ADHD and includes the
following subscales: ADHD Index, Hyperactiv-
ity, Cognitive Problems, and Oppositional.
To assess HRQL, the child’s caregiver com-
pleted the Child Health Questionnaire (CHQ)
(Landgraf et al. 1996). The CHQ is a generic
HRQL measure that has been used in studies
of children with a variety of chronic conditions
including ADHD (Landgraf et al. 1996; Sawyer
et al. 2002). Although a child self-report ver-
sion of the CHQ exists, the parent version was
selected because it is more widely researched,
has normative data available, and may be used
with a broad age range (children 5–18 years of
age). The 50-item parent report version of the
CHQ includes two summary measures (physi-
cal and psychosocial health) and 11 domain
scales. Scales assessing physical functioning,
pain, physical role functioning, and health
perceptions address physical health. Scales
measuring emotional/behavioral role func-
tioning, behavior, mental health, self-esteem,
parental time impact, parental emotional im-
pact, and family functioning examine psy-
chosocial health. The psychometric properties
of the CHQ are described fully in the test man-
ual (Landgraf et al. 1996) and support the in-
ternal consistency ( = 0.66–0.94 for CHQ
scales), factor structure, and validity of the
measure. Higher scores on the CHQ signify
better HRQL.
Procedures
For each participating site, either an Institu-
tional Review Board (IRB) at the site or a cen-
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tralized IRB approved the investigational pro-
cedures. Informed consent was obtained from
each participant’s parent or guardian and as-
sent was obtained from each child. Following
the informed consent process, children were
evaluated to determine whether ADHD diag-
nostic and severity criteria were met without
the presence of any exclusionary criteria. Dur-
ing the first 10 weeks of the study (acute
phase), participants were seen on a weekly
basis. During the long-term phase, visit inter-
vals were every 3 months until either study
completion (24 months) or study discontinua-
tion. Throughout the study, children received
twice-a-day dosing of atomoxetine (morning
and late afternoon) with a target dose of 1.25
mg/kg per day (mean final dose = 1.13, SD =
0.45). The CHQ was completed at baseline,
after acute treatment (10 weeks or discontinua-
tion) and after long-term treatment (24 months
or discontinuation). Clinician ratings on the
ADHD-RS were obtained to examine severity
of core ADHD symptoms at each visit during
the acute and long-term treatment phases.
Children were not permitted to begin new
psychotropic medication treatments during
the trial.
Data analyses
To examine baseline HRQL, t scores were
calculated for the ADHD sample using age-
based norms provided in the CHQ user’s man-
ual (Landgraf et al. 1996). All acute-phase
participants with a baseline CHQ score were
included in this analysis regardless of whether
or not they completed the long-term study.
Due to the longitudinal nature of the study,
age-based norms also were used in all subse-
quent analyses.
Analyses examining the response of treat-
ment included all participants who completed
long-term treatment. The analysis sample was
restricted to this particular group because the
primary interest of this study was long-term
effects of atomoxetine treatment, and the acute
effects from double-blind placebo controlled
trials of atomoxetine have been described else-
where (Michelson et al. 2001; Perwien et al.
2004). Due to the sparseness of the HRQL data
collection points, the primary assessment was
based on change scores between HRQL mea-
surement points rather than employing re-
peated measures models. A sensitivity
analysis, using repeated measures models,
was also conducted. The change scores com-
puted included: (1) Baseline to acute-phase
end point and (2) acute-phase end point to the
end of the long-term treatment phase. Using
intent-to-treat analyses, paired t-tests were
employed to assess whether changes were sta-
tistically different from 0 for completers (i.e.,
participants with 24 months of treatment). To
understand better HRQL changes for partici-
pants who discontinued the investigation pre-
maturely, secondary analyses were conducted
for participants who discontinued long-term
treatment (6 months and <24 months).
To assess the clinical meaningfulness of the
change scores, response rates were calculated.
Although there is no gold standard approach
to dichotomizing scores into response cate-
gories, participants were labeled as responders
if they had an increase of at least one standard
error of measurement (SEM) in their CHQ psy-
chosocial summary score. The SEM, the stan-
dard deviation multiplied by the square root of
1 minus the reliability coefficient, represents a
change above and beyond that expected by
chance for an individual (Wyrwich et al. 1999).
Compared to response definitions based on t
scores, this approach reduces problems due to
participant baseline scores in or near the nor-
mative range. Based on the SEM criterion, par-
ticipants were categorized into four mutually
exclusive groups: (1) Acute and long-term
treatment responder, (2) acute treatment re-
sponder only, (3) long-term treatment respon-
der only, and (4) nonresponder. Because the
SEM criterion simply indicates individual im-
provement as opposed to “normal function-
ing,” percentages of participants within the
normative range (within 1 and 1.5 standard de-
viations of the normed mean) also are reported.
Last, potential predictors of changes during
the long-term phase of the study were as-
sessed. ANOVA models were utilized to assess
long-term changes with the following depen-
dent variables: Investigational site, acute end
point CHQ and ADHD-RS scores, age, gender,
race, ADHD subtype, oppositional defiant dis-
order diagnosis, and previous stimulant use.
716 PERWIEN ET AL.
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RESULTS
Participant characteristics
Of the 912 participants originally enrolled in
the trial, 80% (n = 728) completed the 10 weeks
of atomoxetine treatment (“acute partici-
pants”), 65% (n = 591) completed at least 6
months of treatment (“long-term partici-
pants”), and 34% (n = 312) completed the
entire 24-month study (“completers”). Partici-
pant data for each phase of the study includ-
ing the number of participants retained at each
phase of the trial and the most common rea-
sons for study discontinuation are presented
in Fig. 1.
Table 1 presents characteristics of acute par-
ticipants, long-term participants, and com-
pleters. As shown in Fig. 2, participants in the
present study had baseline CHQ scores that
were significantly lower (indicating worse
HRQL) compared to normative data (Landgraf
et al. 1996). Because the CHQ assesses the past
4 weeks and some long-term participants (n =
209) and completers (n = 132) were treated
with stimulant medications within this time-
frame, it was possible that these participants
had different baseline HRQL scores compared
to untreated participants due to having re-
ceived treatment for ADHD. To examine this
issue, participants were divided into two
groups: Those taking a stimulant within 30
days prior to baseline assessment and those
who had not received any stimulant medi-
cations. Because there was no significant dif-
ference between the groups in baseline
psychosocial HRQL (t = 1.55, p = 0.12), all
other analyses employed the combined group.
Treatment outcomes
Table 2 summarizes HRQL and ADHD core
symptom baseline and change scores for the
completers. Following acute treatment with
atomoxetine, significant improvements were
observed on the psychosocial summary scale
(t statistic = 19.1, p < 0.01) as well as all psy-
chosocial domains (Table 2). Improvements on
the psychosocial summary scale were main-
tained following long-term treatment (t = 0.4, p
= 0.71) and psychosocial subscale improve-
ments were either maintained or slightly im-
proved after 24 months of treatment (Table 2).
Compared to the magnitude of change on the
psychosocial summary scale between baseline
and acute phases, the magnitude of change
from acute to long-term was relatively small.
However, the 24-month scores for the psy-
chosocial summary scale and all psychosocial
domains represent significant improvement
over the study entry scores. The pattern of
HRQL improvements was consistent with
those found for core ADHD symptoms. Specif-
ically, clinician ratings based on parent inter-
views (ADHD-RS Total) and direct parent
reports (CPRS) of ADHD symptoms indicate
significant improvement after acute treatment
(t = 39.6, p < 0.01 and t = 33.2, p < 0.01, re-
spectively), and these improvements were
maintained or slightly improved after long-
term treatment (ADHD-RS Total t = 2.7, p =
0.01 and CPRS t = 1.2, p = 0.23). As expected,
no significant improvements were found on
the CHQ Physical Summary Scale or its related
domain subscales after acute or long-term
treatment.
As noted earlier, 279 long-term participants
discontinued treatment prior to the end of the
24-month study and end point CHQ measure-
ments were available for 182 of these cases. For
these participants, psychosocial functioning
after long-term treatment declined from the
levels observed at the end of the acute phase
(psychosocial summary score mean change =
7.7, SD = 14.4, t = 7.7, p < 0.01). However,
the end point scores still represent an improve-
ment from the original baseline (M = 6.0, SD =
14.6, t = 5.5, p < 0.01). Repeated measures
analysis employing all patients was performed
as a sensitivity analysis for the psychosocial
summary score and showed a similar pattern
as the primary assessment: A significant in-
crease during the acute phase (p < 0.001) fol-
lowed by stability from the acute to long-term
phase (p = 0.360).
Assessment of predictors did not yield con-
sistent results across analyses. Oppositional
defiant disorder, past treatment with stimu-
lants, age, prior HRQL ratings, and ADHD
symptoms were all significant predictors (p <
0.05) of long term improvement in either the
analysis of completers or of all long term par-
LONG-TERM ATOMOXETINE TREATMENT AND HRQL 717
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Assessed for eligibility 
(n = 1046)
Excluded from study 
(n = 132)
Did not meet inclusion criteria (n = 83) 
Refused to participate (n = 32) 
Other reasons (n = 17)
Acute Treatment 
Received treatment (n = 912) 
Did not receive treatment (n = 2)
HRQL Completers Analyses 
Excluded from analyses due to missing CHQ data (n = 17)
Acute Treatment Follow-Up 
Completed treatment (n = 728) 
Lost to follow-up (n = 10) 
Discontinued treatment (n = 174):  
Lack of efficacy  (n = 97) 
Adverse event (n = 21) 
Protocol violation (n = 10) 
Personal conflict/patient decision (n = 34) 
Other (n = 12)
Long-Term Treatment 
Received treatment (n = 591) 
Did not receive long-term treatment (i.e., discontinued at end of or 
after acute treatment, but prior to 6 months of treatment) (n = 137) 
Lack of efficacy (n = 55) 
Adverse event (n = 15) 
Relapse (n = 21) 
Protocol violation (n = 13) 
Personal conflict/patient decision (n = 12) 
Other (n = 21)
Long-Term Follow-Up 
Completed long-term treatment (n = 312) 
Lost to follow-up (n = 32) 
Discontinued treatment (n = 247) 
Lack of efficacy (n = 85) 
Adverse event (n = 15) 
Relapse (n = 24) 
Protocol violation (n = 30) 
Personal conflict/patient decision (n = 52) 
Other (n = 41)
FIG. 1. Flow diagram of trial phases. CHQ = The Child Health Questionnaire; HRQL = health-related quality of life.
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TABLE 1. SAMPLE CHARACTERISTICS
Acute participants Long-term participants Completers
(n = 728) (n = 591) (n = 312)
Age, mean (SD) 11.1 (2.8) 11.1 (2.7) 10.9 (2.6)
Male 76.1% 76.5% 78.2%
Ethnicity
White non-Hispanic 82.8% 82.6% 83.7%
Hispanic 7.3% 7.6% 8.3%
African American 5.6%a 5.2%b 2.6%a,b
Other 4.3% 4.6% 5.5%
ADHD subtype
Hyperactive/impulsive 3.3% 3.0% 4.2%
Inattentive 35.0% 35.9% 35.9%
Mixed 61.7% 61.1% 59.9%
Oppositional defiant disorder 37.2%a 36.0%b 32.1%a,b
History of stimulant treatment 75.6% 75.4% 76.5%
Family history of ADHD 55.1% 54.4% 56.9%
ADHD-RS t score (SD) 78.8 (11.4) 78.7 (11.4) 78.1 (11.9)
Acute participants = participants who completed acute (10 weeks) of treatment; long-term participants = partici-
pants who completed at least 6 months of atomoxetine treatment; completers = participants who completed the en-
tire 24-month study.
SD = standard deviation; ADHD = attention-deficit/hyperactivity disorder; ADHD-RS = ADHD Rating Scale.
aSignificant differences (p < 0.05) between completers and acute participants who were not completers.
bSignificant differences (p < 0.05) between completers and long-term participants who were not completers.
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FIG. 2. Baseline Child Health Questionnaire t scores for acute participants.
14366C08.pgs  12/18/06  11:43 AM  Page 719
ticipants. For the completers, lack of prior
stimulant use, older age, less severe ADHD
symptoms at acute treatment end point, and
worse HRQL at acute treatment end point
were predictive of greater HRQL improve-
ments. In examining all long-term partici-
pants, only worse HRQL following acute
treatment and the lack of oppositional defiant
disorder were predictive of more improved
HRQL.
Response rates
Using the response definition of an im-
provement in the psychosocial summary score
of at least one SEM, the majority of completers
were responders at the end of long-term treat-
ment (Table 3). A total of 81.1% (n = 228) of the
completers were responders at the end of the
acute phase and 78.3% (n = 220) were respon-
ders after 24 months of treatment. Of the com-
pleters who responded after acute treatment,
86% (n = 196) continued to meet response cri-
teria at the end of the study. Consistent with
response rate data for the completers, the ma-
jority of long-term participants met response
criteria at their final measurement (Table 3).
Of the long-term participants who were re-
sponders after the acute phase, 78.4% (n = 283)
continued to meet response criteria at end
point. Using t scores to examine response
rates, the majority of completers were respon-
ders following long-term treatment. Specifi-
cally, 67.3% (n = 189) and 80.1% (n = 225) of
these participants were within the normative
range using 1.0 and 1.5 SD range definitions,
respectively.
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TABLE 2. SUMMARY OF HRQL BASELINE AND CHANGE SCORES IN ADHD FOR COMPLETERS
Baseline to acute Acute to long-term 
Baseline change change
Outcome measure n mean (SD) mean (SD) p mean (SD) p
CHQ t scores (age-based)
Physical summary 281 53.2 (7.9) 0.8 (8.6) 0.117 0.1 (8.1) 0.769
Psychosocial summary 281 29.0 (13.1) 15.1 (13.3) <0.001 0.2 (11.2) 0.709
Behavior 294 32.5 (12.3) 13.6 (11.1) <0.001 0.1 (9.4) 0.813
Family activities 294 29.9 (14.1) 12.2 (13.4) <0.001 0.6 (11.5) 0.375
Parental impact–emotional 292 30.6 (10.8) 10.8 (13.4) <0.001 2.5 (14.0) 0.003
Parental impact–time 294 39.4 (11.6) 8.0 (12.5) <0.001 1.2 (11.4) 0.067
Role–emotional/behavioral 295 32.1 (19.3) 14.2 (21.0) <0.001 0.4 (15.2) 0.682
Self esteem 292 39.6 (11.9) 7.9 (12.1) <0.001 0.8 (11.8) 0.260
Mental health 293 42.4 (13.6) 7.5 (14.0) <0.001 0.7 (11.0) 0.249
All patients with a baseline, acute treatment, and 24-month, long-term treatment score were included in the analysis.
SD = standard deviation; CHQ = Child Health Questionnaire; HRQL = health-related quality of life; ADHD = at-
tention-deficit/hyperactivity disorder.
TABLE 3. RESPONSE RATES FOR LONG-TERM PARTICIPANTS
AND COMPLETERS
Long-term
participants Completers
Responder category (n = 456) (n = 281)
Acute and long-term 62% 70%
treatment responder
Acute treatment only 17% 11%
responder
Long-term treatment only 8% 9%
responder
Nonresponder 13% 10%
Long-term participants = participants completing at
least 6 months of treatment; completers = participants
completing the entire 24-month study.
Response definition is based on the following crite-
rion: a baseline to end point increase of at least one stan-
dard error of measurement (SEM) in CHQ psychosocial
summary score.
Acute and long-term treatment responder = partici-
pant responded after both the acute (10 weeks of treat-
ment) and long-term treatment phases; acute treatment
only responder = participant responded after acute treat-
ment but not after long-term treatment; long-term treat-
ment only responder = participant responded after
long-term treatment but not after acute treatment; non-
responder = participant did not respond after acute or
long-term treatment.
CHQ = Child Health Questionnaire.
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DISCUSSION
At baseline, participants in this study were
experiencing significantly worse HRQL in
areas of psychosocial health compared to nor-
mative data. These findings are consistent
with other investigations (Landgraf et al. 1996;
Sawyer et al. 2002), and indicate that HRQL is
an area of concern for children with ADHD. In
addition, research indicates that HRQL is an
outcome that is not fully captured by the mea-
surement of core ADHD symptomatology
(Matza et al. 2004). Therefore, the assessment
of HRQL should be viewed as a complemen-
tary procedure because HRQL represents a do-
main beyond traditional health status (e.g.,
ADHD core symptoms) by examining the sub-
jective impact of a disorder. In fact, the AAP
also has recognized the importance of evalu-
ating treatment across outcome domains,
including behavioral, academic, and psy-
chosocial functioning (American Academy of
Pediatrics 2001). This type of multidimen-
sional evaluation is likely to capture a full pic-
ture of treatment effectiveness including
meaningful HRQL outcomes such as social
functioning, family relationships, and psycho-
logical functioning.
In terms of outcomes of treatment with
atomoxetine, findings from this study add to
previously published data from acute, double-
blind placebo controlled clinical trials. These
trials, which have examined treatment effects
over relatively short periods of time (i.e., 8–10
weeks), support the efficacy of atomoxetine on
core ADHD symptoms as well as HRQL out-
comes (Michelson et al. 2001; Perwien et al.
2004). The present study further supports ear-
lier results by indicating that the HRQL im-
provements observed after acute treatment
with atomoxetine were generally maintained.
These data suggest that improvements found
after acute treatment were durable rather than
transitory. This pattern is consistent with
changes found for core ADHD symptoms. Fi-
nally, consistent with the symptoms of the dis-
order and data previously reported by
Perwien et al. (2004), HRQL improvements
were specific to areas of psychosocial rather
than physical health.
Although some improvement was observed
from acute to long-term end point related to
the impact of ADHD on parents emotional ad-
justment, the majority of psychosocial HRQL
domains remained stable. One possibility is
that the failure to document further improve-
ment may be due to ceiling effects and/or re-
sponse shift. In a previous study (Perwien et
al. 2004), less psychosocial impairment at base-
line was associated with less improvement fol-
lowing acute treatment with atomoxetine.
Thus, participants who evidenced better base-
line HRQL scores were more limited in the
amount of improvement they could experi-
ence compared to participants who had worse
baseline scores. Therefore, it is possible that
participants in the present study who had high
HRQL at the beginning of the study had less
opportunity to improve significantly beyond
their acute scores. Response shift offers an-
other explanation as to why there were not
further improvements from acute to long-term
treatment for the majority of psychosocial
health scales. It has been defined as, “a change
in the meaning of one’s self-evaluation of
quality of life (QOL) as a result of changes in
internal standards, values, and the conceptual-
ization of QOL” (Sprangers and Schwartz 2000,
p. 14) following a change in health status. Par-
ents in this study may have experienced re-
sponse shift because their children’s health
status (i.e., ADHD core symptoms) improved,
resulting in a change in their internal standard
of HRQL measurement (recalibration). If the
recalibration were more stringent, it would be
more difficult to demonstrate improvement
over the course of long-term treatment.
The findings of this study should be inter-
preted with some caution due to the open-
label study design and the attrition rate.
Despite the open-label design, however, the
acute findings were consistent with double-
blind placebo controlled trials, suggesting that
the design did not unduly bias the results. Fur-
thermore, it could be hypothesized that if the
influence of receiving a medication overly in-
fluenced perceived HRQL, treatment effects
might be less likely to be maintained because
the novelty of the treatment would decrease
over time. Attrition rates are generally a chal-
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lenge for long-term treatment studies, and the
present investigation is no exception. In this
study, only 52.8% of participants who began
long-term treatment completed the full 24-
month study and only 34.2% of the patients
that began acute treatment finished the full 24-
months of the study. It is possible that partici-
pants who completed the study were the most
receptive to treatment with atomoxetine. In
fact, those who remained in the study for the
full 24-month duration had greater improve-
ments on HRQL compared to those who dis-
continued participation prematurely.
Several unanswered issues remain and are
of potential interest for future investigation.
For example, whether HRQL improvements
plateau or fluctuate following long-term treat-
ment cannot be determined from this study
because of the limited measurement points
(i.e., baseline, acute end point, long-term end
point). Future studies should include chil-
dren’s perceptions of their own HRQL. Includ-
ing both parent and child informants would
not only provide a more complete picture of
the effect of treatment on HRQL, but would
also give insight into the consistency between
parent and child reports for children with
ADHD. In fact, some studies indicate that par-
ents and children have different perceptions of
children’s HRQL (Vogels et al. 1998; Sawyer et
al. 1999; Levi and Drotar 1999).
Another area for future investigation is the
effect of multimodal treatment. Although
the MTA study (MTA Cooperative Group
1999) did not indicate superior effects for the
combined treatment arm (medication plus be-
havior therapy) compared to optimally admin-
istered medication alone, it is possible that
some of the HRQL outcomes may be amenable
to combination treatments that include a psy-
chotherapeutic component. In addition, addi-
tional study is needed to assess potential
predictors of improvement further in HRQL.
Finally, atomoxetine appears to be a particu-
larly attractive medication intervention be-
cause it does not have some of the potential
limitations of stimulant medications (Kra-
tochvil et al. 2003) and appears to provide con-
tinuous symptom improvement (Kelsey et al.
2004). Although this study cannot address
whether or not these characteristics of atomox-
etine have a positive effect on HRQL, it is pos-
sible that these factors play a role in improving
HRQL. For example, continuous symptom re-
lief may allow for a child to have improved in-
teractions with family members which may, in
turn, enhance family functioning aspects of
HRQL.
Notwithstanding the aforementioned limi-
tations and examined in conjunction with pre-
vious findings (Michelson et al. 2001; Perwien
et al. 2004), this study supports the positive re-
sponse to atomoxetine treatment on HRQL in
children and adolescents. As these data indi-
cate, improved HRQL is present following
acute treatment and is maintained over long-
term treatment. Although medications for
chronic conditions, such as ADHD, are de-
veloped to improve specific symptoms and
evaluated on disease-related health status
measures (e.g., core ADHD symptoms), suc-
cessful treatment may be better indicated by
improvement in both health status and func-
tional outcomes. This may be especially im-
portant in chronic conditions that have been
documented to be associated with relatively
poor HRQL. The present investigation pro-
vides a model for evaluating ADHD treatment
on domains of functioning not previously doc-
umented in other studies.
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